title: Down-regulation of miR-21 Induces Differentiation of Chemoresistant Colon Cancer Cells and Enhances Susceptibility to Therapeutic Regimens.
abstract: MicroRNAs are endogenous posttranscriptional modulators that negatively control the expression of their target genes and play an important role in the development and progression of many malignancies, including colorectal carcinoma. In particular, expression of microRNA-21 (miR-21) is greatly increased in chemotherapy-resistant (CR) colon cancer cells that are enriched in undifferentiated cancer stem/stem-like cells (CSCs/CSLCs). We hypothesize that miR-21 plays a critical role in regulating differentiation of CR colon cancer cells. Indeed, we observed that downregulation of miR-21 in CR colon cancer cells (HCT-116 or HT-29) by antisense miR-21 induced differentiation, as evidenced by marked increases in cytokeratin-20 (CK-20) expression and alkaline phosphatase activity. These changes were accompanied by a significant reduction in the expression of colon CSC/CSLC marker CD44, colonosphere formation, and T-cell factor/lymphoid enhancer factor (TCF/LEF) activity but increased the expression of proapoptotic programmed cell death 4 gene. Induction of differentiation greatly increased sensitivity of CR colon cancer cells to the growth inhibitory properties of all three regimens tested: 5-fluorouracil + oxaliplatin (FUOX), difluorinated curcumin (CDF), and the combination of CDF and FUOX. However, the magnitude of inhibition of growth by either CDF (75%) alone or CDF + FUOX (80%) was much higher than that observed with only FUOX (40%). Growth inhibition by CDF and CDF + FUOX in differentiating CR colon cancer cells was associated with a 98% to 99% reduction in the expression of CD44 and epidermal growth factor receptor (EGFR). However, down-regulation of CK-20 in CR colon cancer cells produced no significant change in cellular growth in the absence or presence of FUOX, when compared with the corresponding controls. The current observation suggests that CDF and CDF + FUOX are highly effective in inhibiting growth and reducing colon CSCs/CSLCs in anti-miR-21-induced differentiating CR colon cancer cells and supports our contention that differentiation enhances susceptibility of CR cancer cells to conventional and nonconventional therapeutic regimen.
authors.affiliation: John D. Dingell VA Medical Center, Wayne State University, Detroit, MI ; Department of Internal Medicine, Wayne State University, Detroit, MI.
authors.forename: Yingjie
authors.initials: Y
authors.lastname: Yu
authors.forename: Fazlul H
authors.initials: FH
authors.lastname: Sarkar
authors.forename: Adhip P N
authors.initials: AP
authors.lastname: Majumdar
references.citation: Digestion. 2002;66(3):131-44
references.pmid: 12481159
references.citation: Cancer Res. 1998 Mar 15;58(6):1130-4
references.pmid: 9515795
references.citation: Science. 1997 Mar 21;275(5307):1787-90
references.pmid: 9065402
references.citation: Dev Cell. 2006 Oct;11(4):441-50
references.pmid: 17011485
references.citation: Oncogene. 2008 Apr 3;27(15):2128-36
references.pmid: 17968323
references.citation: Mol Cancer Ther. 2005 Mar;4(3):435-42
references.pmid: 15767552
references.citation: Int J Cancer. 2008 Jan 15;122(2):267-73
references.pmid: 17918158
references.citation: J Biol Chem. 2011 Mar 25;286(12):10764-72
references.pmid: 21252226
references.citation: J Mol Signal. 2011 Jul 20;6:7
references.pmid: 21774804
references.citation: Cancer Res. 2010 May 1;70(9):3606-17
references.pmid: 20388782
references.citation: Transl Oncol. 2009 Dec;2(4):321-8
references.pmid: 19956394
references.citation: Mol Cancer. 2010 Aug 06;9:212
references.pmid: 20691072
references.citation: Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10158-63
references.pmid: 17548814
references.citation: N Engl J Med. 2006 Sep 21;355(12):1253-61
references.pmid: 16990388
references.citation: Biochem Biophys Res Commun. 2009 Jan 16;378(3):344-7
references.pmid: 19010307
references.citation: Nat Rev Cancer. 2005 Apr;5(4):275-84
references.pmid: 15803154
references.citation: Anticancer Res. 2010 Feb;30(2):319-25
references.pmid: 20332435
references.citation: Carcinogenesis. 2012 Jan;33(1):68-76
references.pmid: 22072622
references.citation: Virchows Arch. 2008 Jan;452(1):1-10
references.pmid: 18040713
references.citation: Pharm Res. 2011 Apr;28(4):827-38
references.pmid: 21161336
references.citation: Oncogene. 2008 Jul 17;27(31):4373-9
references.pmid: 18372920
references.citation: Am J Physiol Gastrointest Liver Physiol. 2011 Aug;301(2):G347-55
references.pmid: 21596996
references.citation: Curr Drug Targets. 2010 Aug;11(8):926-35
references.pmid: 20415649
references.citation: J Am Med Inform Assoc. 2012 Mar-Apr;19(2):156-60
references.pmid: 22101905
references.citation: Front Biosci (Landmark Ed). 2011 Jan 01;16:1651-62
references.pmid: 21196254
references.citation: Nature. 2010 Sep 2;467(7311):86-90
references.pmid: 20693987
references.citation: Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1936-41
references.pmid: 19188603
references.citation: Science. 2002 Sep 20;297(5589):2056-60
references.pmid: 12154197